Top life sciences deals of 2025 point to selective growth

Version 2

PharmaShots’ new “Top 20 Life Sciences Deals of 2025,” produced with DealForma data, offers a snapshot of a year when biopharma dealmaking regained momentum and strategic discipline. The list highlights how 2025’s biggest transactions clustered around proven commercial assets, late-stage pipelines, and high-conviction therapeutic areas, rather than broad, speculative platform bets. Among the headline deals were Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies, Roche’s obesity-focused partnership with Zealand Pharma worth up to $5.3 billion, and Bain Capital’s carve-out acquisition of Mitsubishi Tanabe Pharma for about ¥510 billion. The tone of the market was not just visible in M&A and licensing: PharmaShots’ “Top 20 Healthcare IPOs of 2025,” also based on DealForma data, described sustained investor confidence across biotech, medtech, digital health, and AI-enabled healthcare, with the year’s largest raises favoring scaled platforms, precision medicine, advanced diagnostics, and revenue-generating businesses. (pharmashots.com)

That fits the wider backdrop. DealForma’s quarterly review found strong life sciences activity in early 2025, including 169 R&D partnerships worth $60.4 billion in Q1 alone, while Deloitte reported that by the end of November 2025, life sciences M&A had reached 193 transactions totaling $220 billion, surpassing 2024’s total deal value. At the same time, Deloitte described the year as uneven: macroeconomic pressure, inflation, and regulatory uncertainty slowed activity early, before a stronger rebound later in the year. In other words, 2025 wasn’t a return to indiscriminate dealmaking, it was a return to selective, high-value dealmaking. The financing side supports that interpretation too. Blackstone closed Blackstone Life Sciences VI at its $6.3 billion hard cap, making it the largest life sciences vehicle of its kind and about 40% larger than its predecessor, a sign that major pools of capital are still being assembled for drug and medtech investing even as buyers stay choosy. (dealforma.com)

The individual transactions help explain that shift. J&J’s acquisition of Intra-Cellular Therapies strengthened its neuroscience portfolio around Caplyta, a marketed CNS drug, and gave the company a clearer post-Stelara growth lever. Roche’s deal with Zealand Pharma reflected the industry’s race to build obesity pipelines, with Zealand receiving $1.7 billion upfront and the potential for billions more in milestones under a co-development and co-commercialization structure. Bain Capital’s move on Mitsubishi Tanabe Pharma showed that private equity also remained active in life sciences, especially where a legacy pharma business could be repositioned as a standalone growth platform. And private equity interest extended beyond carve-outs: CVC Capital Partners proposed a roughly €10.9 billion take-private of Recordati, valuing the company at €52 per share and underscoring continued appetite for established specialty pharma businesses, including those with rare-disease exposure after Recordati’s earlier expansion through the EUSA Pharma acquisition. (investor.jnj.com)

Industry commentary around the year’s deals has pointed in the same direction. Nature’s midyear review of biopharma dealmaking, drawing on DealForma, described 2025 as a year of renewed excitement driven by notable high-value mergers and acquisitions. Deloitte, meanwhile, said buyers increasingly targeted assets in areas such as cardiovascular disease, oncology, neurovascular disease, and mature technologies with clearer growth potential. The IPO market echoed some of those same preferences. PharmaShots’ IPO roundup said 2025 capital raising showed a clear shift toward AI-driven drug discovery, precision medicine, digital care platforms, and continued momentum in oncology and metabolic therapies, with Medline Industries’ $7.2 billion raise far ahead of other offerings such as Caris Life Sciences and Lumexa Imaging. That suggests the market rewarded strategic fit and operational readiness more than early-stage optionality alone, whether companies were pursuing a sale, a partnership, or a public listing. (nature.com)

Why it matters: For veterinary professionals, the list is less about any single deal and more about the market signal underneath it. Capital allocation in human life sciences often influences the broader health innovation ecosystem, including diagnostics, specialty therapeutics, contract research, manufacturing, and digital infrastructure that can also affect veterinary medicine. When large buyers concentrate spending on assets with established demand, stronger evidence packages, cleaner commercialization stories, and increasingly AI-enabled or precision-focused capabilities, animal health companies, veterinary startups, and practice-facing suppliers may face a tougher bar for funding, partnerships, and exits, but they may also benefit if investors start looking for adjacent markets with clearer economics and less crowding. That’s an inference based on how cross-sector health care capital tends to move, rather than a direct claim from the deal reports themselves. (dealforma.com)

There’s also a practical workforce and supply-chain angle. Big human-health transactions can reshape competition for scientific talent, manufacturing slots, AI capabilities, and external development partners. Veterinary companies don’t operate in isolation from those pressures. If obesity, CNS, specialty pharma, rare disease, and tech-enabled care models continue to command outsized investment in human medicine, veterinary innovators may need to work harder to differentiate their clinical and commercial case to investors and strategic partners. This is especially relevant for companies developing companion animal therapeutics, diagnostics, or tech-enabled care models that compete for overlapping capital and expertise. The presence of large dedicated funds such as Blackstone’s BXLS VI also suggests that capital is available, but likely on terms that favor de-risked programs and clearer paths to value creation. (deloitte.com)

What to watch: In 2026, the key question is whether this selective deal environment broadens into adjacent sectors, including animal health and veterinary services, or stays concentrated in high-profile human biopharma categories. If macro conditions remain steadier and buyers keep favoring de-risked assets, veterinary businesses with strong revenue visibility, differentiated clinical evidence, platform value, or credible AI-enabled workflows could become more attractive targets for partnership or consolidation. It will also be worth watching whether private equity keeps leaning into take-private and carve-out strategies, and whether IPO investors continue rewarding scaled healthcare platforms over earlier, less commercial stories. (deloitte.com)